Copyright
©The Author(s) 2018.
World J Gastroenterol. Sep 7, 2018; 24(33): 3738-3748
Published online Sep 7, 2018. doi: 10.3748/wjg.v24.i33.3738
Published online Sep 7, 2018. doi: 10.3748/wjg.v24.i33.3738
Ref. | Drugs | Experimental models | Effects |
Fernandez et al[46] | Rapamycin and glivec | Partial portal vein ligation | Downregulates VEGF, VEGFR2, CD31, PDGF, PDGFR-β, and α-SMA |
Mejias et al[19] | Sorafenib | Partial portal vein ligation and CCl4-induced cirrhosis | Blocks VEGF, PDGF, and Raf/MEK/ERK signaling pathway; therefore, reduces intraorgan and systemic blood flow, splanchnic neovascularization, portosystemic shunting, hepatic vascular resistance, and portal pressure |
Woltering et al[49], Mejias et al[50] | Somatostatin and its synthetic analogs | Partial portal vein ligation | Reduces VEGF and CD31 expression, splanchnic neovascularization, and portosystemic collateral circulation by blocking SSTR2 |
Miternique-Grosse et al[55] | Spironolactone | Biliary cirrhosis | Suppresses the effects of aldosterone and the VEGF signal transduction pathway |
Lee et al[58] | N-acetylcysteine | Biliary cirrhosis | Reduces oxidative stress, inflammatory cytokine levels, TNF-α, VEGF, VEGFR2, Ang1, CD31 expression, and suppresses Akt/eNOS/NO pathway |
Hsu et al[61] | Bosentan and ambrisentan | Biliary cirrhosis | Block endothelin receptors and suppress iNOS, cyclooxygenase 2, VEGF, VEGFR2, and Akt signaling |
Schwabl et al[64] | Pioglitazone | Biliary cirrhosis | Downregulates inflammatory genes and NF-κB expression, suppresses angiogenic and pro-inflammatory cytokines, chemokines, and growth factors (VEGF, PDGF, and PIGF) |
Li et al[66] | Thalidomide | Biliary cirrhosis | Hinders TNF-α/interleukin-1β production and blocks the TNFα-VEGF-NOS-NO pathway |
Hsu et al[67] | Catechins of Camellia sinensis | Biliary cirrhosis | Reduce HIF-1α expression, Akt signaling, and VEGF synthesis |
Hsin et al[68] | 2’-hydroxyflavonoid | Thioacetamide-induced liver cirrhosis | Downregulates apoptosis |
Hsu et al[69] | Curcumin | Biliary cirrhosis | Suppresses VEGF, cyclooxygenase 2, and eNOS |
- Citation: Garbuzenko DV, Arefyev NO, Kazachkov EL. Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives. World J Gastroenterol 2018; 24(33): 3738-3748
- URL: https://www.wjgnet.com/1007-9327/full/v24/i33/3738.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i33.3738